Tested Applications
| Positive WB detected in | etoposide treated HT-29 cells, HSC-T6 cells, UV treated HSC-T6 cells |
| Positive IF/ICC detected in | etoposide treated HT-29 cells, HT-29 cells |
Recommended dilution
| Application | Dilution |
|---|---|
| Western Blot (WB) | WB : 1:1000-1:4000 |
| Immunofluorescence (IF)/ICC | IF/ICC : 1:200-1:800 |
| It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
| Sample-dependent, Check data in validation data gallery. | |
Product Information
28961-1-AP targets Phospho-P53 (Ser15) in WB, IHC, IF/ICC, ELISA applications and shows reactivity with human, rat samples.
| Tested Reactivity | human, rat |
| Cited Reactivity | human, mouse, rat |
| Host / Isotype | Rabbit / IgG |
| Class | Polyclonal |
| Type | Antibody |
| Immunogen |
Peptide Predict reactive species |
| Full Name | tumor protein p53 |
| Calculated Molecular Weight | 44 kDa |
| Observed Molecular Weight | 53 kDa |
| GenBank Accession Number | BC003596 |
| Gene Symbol | P53 |
| Gene ID (NCBI) | 7157 |
| RRID | AB_2881236 |
| Conjugate | Unconjugated |
| Form | Liquid |
| Purification Method | Antigen affinity purification |
| UNIPROT ID | P04637 |
| Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol, pH 7.3. |
| Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. 20ul sizes contain 0.1% BSA. |
Background Information
The p53 tumor suppressor protein plays a major role in cellular response to DNA damage and other genomic aberrations. Activation of p53 can lead to either cell cycle arrest and DNA repair or apoptosis . DNA damage induces phosphorylation of p53 at Ser15 and Ser20 and leads to a reduced interaction between p53 and its negative regulator, the oncoprotein MDM2. p53 can be phosphorylated by ATM, ATR, and DNA-PK at Ser15 and Ser37. Phosphorylation impairs the ability of MDM2 to bind p53, promoting both the accumulation and activation of p53 in response to DNA damage.
Protocols
| Product Specific Protocols | |
|---|---|
| IF protocol for Phospho-P53 (Ser15) antibody 28961-1-AP | Download protocol |
| WB protocol for Phospho-P53 (Ser15) antibody 28961-1-AP | Download protocol |
| Standard Protocols | |
|---|---|
| Click here to view our Standard Protocols |
Publications
What published studies show
Phospho-P53 (Ser15) Polyclonal antibody (Cat# 28961-1-AP) has 57 citations. Publications appear in journals including Nature Communications, Advanced Science, Journal of Experimental & Clinical Cancer Research, Cell Death & Disease, Cell Death Discovery, International Journal of Molecular Sciences, Toxicology, and Scientific Reports, among others. Research fields span oncology (lung, breast, gastric, pancreatic, and glioblastoma cancers), cellular senescence, apoptosis, DNA damage response, cardiology, neurology, skin photodamage, osteoarthritis, atherosclerosis, autophagy, and ferroptosis.
| Species | Application | Title |
|---|---|---|
Bioact Mater Dual-modal antioxidant and epigenetic synergy attenuates the self-perpetuating senescence cycle in osteoarthritis. | ||
Nat Commun 10-hydroxy-2-decenoic acid prevents osteoarthritis by targeting aspartyl β hydroxylase and inhibiting chondrocyte senescence in male mice preclinically | ||
Gut Microbes Exosomal-miR-129-2-3p derived from Fusobacterium nucleatum-infected intestinal epithelial cells promotes experimental colitis through regulating TIMELESS-mediated cellular senescence pathway | ||
J Nanobiotechnology Synergistic microenvironment therapy: a dual-function nanogel of supramolecular collagen ll-mimetic matrix and antioxidant MXene for attenuating intervertebral disc degeneration. | ||
J Exp Clin Cancer Res Two-polarized roles of transcription factor FOSB in lung cancer progression and prognosis: dependent on p53 status | ||
Adv Sci (Weinh) Transgelin Promotes Glioblastoma Stem Cell Hypoxic Responses and Maintenance Through p53 Acetylation |
